Abreos Biosciences, a San Diego, CA-based healthcare company advancing technology for precision dosing of biologics, raised a seed round of funding of undisclosed amount.
The round was led by Triton Technology Fund (TTF).
The company intends to use the funds to accelerate their commercialization plan, expand their marketing and business development teams, and establish major clinical research partnerships in the US and Europe.
Founded in 2013 at UC San Diego by Dr. Bradley Messmer (CEO) and Dr. Thomas Kipps, and also led by Neil Senturia (executive chairman), Abreos has issued patent for developing point-of-care devices that monitor the levels of biologic drugs in patients for precision dose guidance.
With this capability, patients can ensure they are receiving and maintaining the right amount of these expensive and efficacious medications.
The company has developed tests for the top biologic drugs used in autoimmune and neurology disorders, and cancer.